Michael J. Pellini - 26 May 2021 Form 3 Insider Report for Singular Genomics Systems, Inc.

Role
Director
Signature
/s/ Michael J. Pellini
Issuer symbol
N/A
Transactions as of
26 May 2021
Net transactions value
$0
Form type
3
Filing time
26 May 2021, 20:36:41 UTC
Next filing
01 Jun 2021
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
holding OMIC Common Stock 72,455 26 May 2021 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding OMIC Series A Preferred Stock 26 May 2021 Common Stock 96,944 $0.000000 By The Pellini Family Trust F1, F2
holding OMIC Employee Stock Option (right to buy) 26 May 2021 Common Stock 60,668 $0.2108 Direct F3
holding OMIC Employee Stock Option (right to buy) 26 May 2021 Common Stock 27,500 $22.43 Direct F4
holding OMIC Employee Stock Option (right to buy) 26 May 2021 Common Stock 60,000 $0.6300 Direct F5
holding OMIC Employee Stock Option (right to buy) 26 May 2021 Common Stock 34,271 $0.2350 Direct F6
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The Series A Preferred Stock shall automatically convert into shares of the Issuer's common stock, par value $0.0001 per share (the "Common Stock"), on a one-for-one basis, immediately prior to the closing of the Issuer's initial public offering. The Series A Preferred Stock has no expiration date.
F2 The Reporting Person is the trustee of The Pellini Family Trust and has voting and dispositive power with respect to these shares.
F3 Option granted under the Singular Genomics Systems, Inc. 2016 Stock Plan. The option shares vest and become exercisable in 48 equal monthly installments beginning on July 21, 2017.
F4 Option granted under the Singular Genomics Systems, Inc. 2016 Stock Plan. The option shares vest and become exercisable upon the earlier of the 2022 Stockholder Annual Meeting or May 5, 2022.
F5 Option granted under the Singular Genomics Systems, Inc. 2016 Stock Plan. The option shares vest and become exercisable in 12 equal monthly installments beginning on January 18, 2020.
F6 Option granted under the Singular Genomics Systems, Inc. 2016 Stock Plan. The option shares vest and become exercisable in 12 monthly installments beginning on January 12, 2019.

Remarks:

Exhibit 24 - Power of Attorney